Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Raw Materials for 3 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials rose 162.92% year-over-year to $17.1 million, compared with a TTM value of $17.1 million through Dec 2025, up 162.92%, and an annual FY2025 reading of $17.1 million, up 162.92% over the prior year.
  • Raw Materials was $17.1 million for Q4 2025 at Catalyst Pharmaceuticals, up from $12.1 million in the prior quarter.
  • Across five years, Raw Materials topped out at $17.1 million in Q4 2025 and bottomed at $1.9 million in Q4 2023.
  • Average Raw Materials over 3 years is $7.9 million, with a median of $6.7 million recorded in 2024.
  • The sharpest move saw Raw Materials soared 241.26% in 2024, then fell 7.34% in 2025.
  • Year by year, Raw Materials stood at $1.9 million in 2023, then skyrocketed by 241.26% to $6.5 million in 2024, then soared by 162.92% to $17.1 million in 2025.
  • Business Quant data shows Raw Materials for CPRX at $17.1 million in Q4 2025, $12.1 million in Q3 2025, and $5.2 million in Q2 2025.